Compile Data Set for Download or QSAR
maximum 50k data
Found 56 of ic50 for UniProtKB: Q07820
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608356((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-1...)
Affinity DataIC50:  2nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608352((Z)-15-chloro-13,25,61-trimethyl-21-(2- (methylami...)
Affinity DataIC50:  4nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608391((Z)-15-chloro-13,21,25,61-tetramethyl-4- ((trifluo...)
Affinity DataIC50:  5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608376((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608393((Z)-15-chloro-96-fluoro-13,21,23,61- tetramethyl-4...)
Affinity DataIC50:  5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM333146(Compound I | US10196404, Example 1 | US10196404, E...)
Affinity DataIC50:  7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608382((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608233((Z)-15-chloro-13,61-dimethyl-26,27-dihydro- 11H,24...)
Affinity DataIC50:  7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608390((Z)-15-chloro-13,21,25,61-tetramethyl-4- (methylsu...)
Affinity DataIC50:  8nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608383((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  9nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608347((Z)-15-chloro-13,21,25,61-tetramethyl- 11H,21H,61H...)
Affinity DataIC50:  9nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608361((Z)-15-chloro-13,96-difluoro-21,25,61- trimethyl-1...)
Affinity DataIC50:  10nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608363((Z)-15,96-difluoro-13,21,25,61-tetramethyl- 11H,21...)
Affinity DataIC50:  10nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608392((Z)-15-chloro-13,21,23,61-tetramethyl-4- (methylsu...)
Affinity DataIC50:  12nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608384((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  13nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608351((Z)-13,15-dichloro-21,25,61-trimethyl- 11H,21H,61H...)
Affinity DataIC50:  14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608346((Z)-15-chloro-96-fluoro-13,61-dimethyl-26,27- dihy...)
Affinity DataIC50:  14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608345(US11691989, Compound 3 | Z)-15-chloro-96-fluoro-13...)
Affinity DataIC50:  14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608340(US11691989, Compound 2 | Z)-15-chloro-96-fluoro-13...)
Affinity DataIC50:  14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608372((Z)-15-chloro-96-fluoro-13,21,23,61- tetramethyl-1...)
Affinity DataIC50:  14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608370(US11691989, Compound 26 | Z)-15-chloro-13,23,61-tr...)
Affinity DataIC50:  14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608362((Z)-15-cyano-96-fluoro-13,21,25,61- tetramethyl-11...)
Affinity DataIC50:  14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608379((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608359((Z)-15-chloro-96-fluoro-61-isopropyl-13,21,25- tri...)
Affinity DataIC50:  15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608371((Z)-15-chloro-21-(2-methoxyethyl)-13,23,61- trimet...)
Affinity DataIC50:  15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608360((Z)-15-chloro-25-(difluoromethyl)-96-fluoro- 13,21...)
Affinity DataIC50:  15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608368((Z)-15-chloro-96-fluoro-21,25,61-trimethyl-13- (tr...)
Affinity DataIC50:  15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608364((Z)-96-fluoro-13,15,21,25,61-pentamethyl- 11H,21H,...)
Affinity DataIC50:  15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608353((Z)-15-chloro-21-(2-methoxyethyl)-13,25,61- trimet...)
Affinity DataIC50:  15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608375((Z)-15-chloro-4-(cyclopropylsulfonyl)-96- fluoro-1...)
Affinity DataIC50:  16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608365((Z)-15-chloro-96-fluoro-21,25,61-trimethyl-13- (((...)
Affinity DataIC50:  16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608389((Z)-15-chloro-25-(difluoromethyl)-96-fluoro- 13,21...)
Affinity DataIC50:  16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608385((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608347((Z)-15-chloro-13,21,25,61-tetramethyl- 11H,21H,61H...)
Affinity DataIC50:  17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608395((Z)-15-chloro-96-fluoro-13,61-dimethyl-4-(2- (meth...)
Affinity DataIC50:  17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608374((Z)-15-chloro-96-fluoro-13,61-dimethyl-4- (methyls...)
Affinity DataIC50:  17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608354((Z)-13-(acetamidomethyl)-15-chloro-21,25,61- trime...)
Affinity DataIC50:  18nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608356((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-1...)
Affinity DataIC50:  19nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608355((Z)-15-chloro-96-fluoro-21,25,61-trimethyl- 11H,21...)
Affinity DataIC50:  19nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608394((Z)-15-chloro-96-fluoro-4-(2-methoxyethyl)- 13,61-...)
Affinity DataIC50:  20nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608369((Z)-15-chloro-13-cyano-96-fluoro-21,25,61- trimeth...)
Affinity DataIC50:  21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608396((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608350((Z)-15-chloro-13-ethyl-21,25,61-trimethyl- 11H,21H...)
Affinity DataIC50:  21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608386((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  22nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608387((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  22nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608388((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  23nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608399(US11691989, Compound 55 | Z)-15-chloro-96-fluoro-1...)
Affinity DataIC50:  24nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608380((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  27nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608398((Z)-15-chloro-4-(2-(dimethylamino)-2- oxoethyl)-96...)
Affinity DataIC50:  27nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Homo sapiens (Human))
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608381((Z)-15-chloro-96-fluoro-13,21,25,61- tetramethyl-4...)
Affinity DataIC50:  29nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: